Chapter 56 Progress in Short-term Human Hibernation Technology
"Come on, everyone, please take a seat. I'm glad that you have joined Light Armor Technology and are willing to listen to my advice and take a chance on the future of the stars and the sea.

We have recruited a total of 2 PhDs and 10 masters this time. Among them, Dr. Li graduated from Beihang University. His previous field of work was somewhat related to hibernation technology. Dr. Li followed me to carry out research on human hibernation technology. I have a very clear idea of ​​the roadmap, and the follow-up is nothing more than breaking through the technologies in the roadmap one by one.

In my opinion, it’s very easy.”

Dr. Li’s real name is Li Ming. He just graduated with a Ph.D. not long ago. He used to work in R&D at a foreign-funded pharmaceutical company, but was poached before he even finished his probation period.

In recent years, the overall business of foreign companies in China has shrunk, especially the R&D centers of pharmaceutical companies in China. For these pharmaceutical companies, the popularization of centralized procurement in China has caused their profits to shrink. The shrinking profits and the gradual maturity of pharmaceutical R&D outsourcing have caused them to gradually lay off their domestic R&D teams.

Even though Li Ming joined a very core team of this foreign company, he couldn't help but smell the danger and finally chose to join Guangjia Technology.

Li Ming was a little confused after listening to this. He himself didn't even know that the field he was previously engaged in was related to hibernation technology.

"In addition, Dr. Hou is mainly responsible for the pharmaceutical R&D outsourcing business. We will take on some pharmaceutical outsourcing business in the early stage to maintain cash flow and train the team.

As the company gradually develops, we will develop new drugs ourselves and will not engage in pharmaceutical outsourcing business.”

Chen Yuanguang gathered his small team of 15 people, plus Lin Jia, a total of 16 people, in a small conference room in Caohejing Biopark to hold the first full-staff meeting. He stood in front and looked at these employees, feeling like he had thousands of troops and was full of passion.

"At present, the company's main business is these two areas. In addition, because of human hibernation technology, we have seen a lot of science fiction works. For example, interstellar travel often involves this technology. The male protagonist enters a hibernation state, and after waking up, two years have passed and he has arrived at the target planet.

Of course, this is human hibernation technology, it is long-term human hibernation technology. What we are currently trying to achieve is short-term hibernation technology, which can allow humans to enter hibernation state for 3 to 10 days.

The time can be as short as three days or as long as ten days.

I divide human hibernation technology into three categories: short-term hibernation, long-term hibernation and cryonics. "

Chen Yuanguang wrote down these three categories on the whiteboard behind him, "I just briefly talked about short-term hibernation and long-term hibernation, so what is cryonics?
Simply put, this is freezing time and reducing the metabolic rate to a negligible level. When you wake up again, it will be decades in the future. The hibernation state is longer, and the unit of measurement is changed from years to decades.

What we are trying to achieve now is short-term hibernation technology.”

After I finished speaking, the audience began to applaud because it sounded much more credible.

For a startup, it is important to let everyone know what you want to do and what your goals are, so that initial cohesion can be formed.

"In terms of pharmaceutical outsourcing, we will cooperate with companies such as Sinopharm, Fosun, and Hengrui. In the early stage, we may focus on the research and development of broad-spectrum vaccines. I am more familiar with this type of business. In addition, Renjie, we will not accept orders from Zhifei Biological, because they have said they will not cooperate with me."

Everyone present smiled in tacit understanding. They were just a startup company, and challenging a listed company with a market value of 200 billion RMB, but it sounded so natural when Chen Yuanguang said this.

The research and development progress of short-term human hibernation technology is much faster than expected.

From the time Guangjia Technology was founded to the middle of the year, they initially used experimental monkeys in the laboratory to successfully put it into hibernation.

"Has the dividend from Tencent not arrived yet?" Chen Yuanguang asked.

It's very urgent. The progress is now far beyond expectations, but the money has been almost spent. In half a year, 50 million has been burned through.

Due to the spread of the virus, the demand for experimental monkeys has surged, and the shortage of supply has led to a surge in prices. The price of an experimental monkey has soared from 12 RMB to 50 RMB, which is simply more exaggerated than robbing money. Moreover, their hibernation technology is not enough to rely on experimental monkeys alone, and it needs to enter the clinical trial stage.

This will cost even more money.

Lin Jia sighed: "Geely is delaying as much as possible. There is no news yet. How about we do the first round of financing?

I looked at the experimental results and they are very good. If we want to sell this technology globally in the future, we will definitely need some influential financial institutions to help us speed up the acquisition of relevant qualifications and help us build a sales system in various places.

Now is a good time to raise funds.”

Chen Yuanguang said: "The problem is that all the financing now is for laboratory products, and the valuation cannot be raised."

Lin Jia said: "This is not a problem. There are so many ways to invest now. We can sign a bet and set a target.

Or if you don't mind, I can borrow money from my family?"

Chen Yuanguang shook his head: "How much can you borrow from your family?
If you borrow more, your father won't be able to understand this technology. If you borrow less, it will be a drop in the bucket. Just the follow-up experiments, plus the first, second and third phases of domestic clinical trials, will require at least 200 million yuan.

If we want to enter the overseas market, I talked to Sun Renjie last time and the starting point is 10 billion yuan. "

Lin Jia thought about it and agreed. Her family was in the traditional industry and it was unlikely for them to invest in the biopharmaceutical industry, let alone invest hundreds of millions of dollars.

"Looking for Lei Jun?" Lin Jia asked.

Chen Yuanguang said: "You can approach them, but not just them. Look for a few more, a few investment institutions, and finally bring them together to discuss.

Let’s talk about it first.”

With Chen Yuanguang's reputation as an endorsement, Shenhai has many investment institutions and they are all very respectful. Why not take an afternoon to come and listen?
Foreign capital came from Sequoia and Morgan, and domestic capital came from CMB International, Shunwei Capital, Qiming Venture Partners and Bencao Capital.

Shunwei Capital attached great importance to it and sent its vice president, and other investment institutions also had senior investment managers.

"We have found neurons that control metabolism in the mammalian brain and discovered that hibernation-related neurons and genes exist in monkeys.

We have achieved the goal of allowing the body to lower its body temperature and enter hibernation simply through external induction.

Through ultrasonic induction, monkeys that originally had no hibernation habit were put into hibernation.

At the same time, through the use of drugs, the experimental monkeys were kept in a hibernation state for five days, and their metabolism dropped to a very low level. According to physical examinations and mental state analysis, no side effects have been found so far." Chen Yuanguang briefly introduced their current achievements, and then continued: "The main purpose of our current round of fundraising is to conduct clinical trials, first find relevant neurons in the human body, and then replicate the success in experimental monkeys."

　Please pursue reading and monthly votes!

　　
　
(End of this chapter)